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DiagnosisAbstract Danoﬂoxacin, a ﬂuoroquinolone derivative antibiotic, was synthesized, successfully
labeled with technetium-99m and formulated for the development of a potential diagnostic imaging
agent of the bacterial infection and inﬂammation with higher efﬁciency than that of the
commercially available 99mTc-ciproﬂoxacin. Factors affecting the labeling yield were optimized.
The radiolabeled antibiotic was subjected to preclinical assessments such as purity, stability, and
pharmacokinetic investigations in animals. The biodistribution studies indicated that the uptake
of 99mTc-danoﬂoxacin was high in the infectious lesion (T/NT = 7.2 ± 0.1) at 2 h post injection.
The abscess to normal ratio indicated that the danoﬂoxacin tracer can be used for infection diagno-
sis. The radiolabeled compound was cleared quickly from most of the body organs. The results dis-
played that 99mTc-danoﬂoxacin could not differentiate between infection and sterile inﬂammation.
ª 2014 TheAuthors. Production and hosting by Elsevier B.V. on behalf of King SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The rate of morbidity and mortality could be reduced if infec-
tion and inﬂammation can be clinically diagnosed and treated
with appropriate drugs at early stage (Qaiser et al., 2010).
Modern imaging techniques and procedures for diagnosis
of infection such as Magnetic Resonance Imaging (MRI),Computer Tomography (CT), X-ray and Ultrasonography
(US) are commercially available and have been used for the
detection of infection. These tools are not the appropriate
methods for the diagnosis and localization of infection at early
stages because they cannot reveal the change in the morphol-
ogy of tissues following the abscess formation (Motaleb,
2007; Lucignani, 2007 and Gemmel et al., 2009). The role of
several Nuclear Medicine Scintigraphy (NMS) techniques in
early diagnosis or discrimination between infection and
inﬂammation is clinically vital for the appropriate manage-
ment of patients with microbial infectious or inﬂammatory
diseases (Saha, 2004; Lupetti et al., 2007 and Langer et al.,
2005). The introduction of a number of radiopharmaceuticals
in Nuclear Medicine used as infection imaging agents was
reported including radiolabeled leukocytes and 67Ga-citrate
(Palestro, 2007 and Yapar et al., 2001). Due to the
Tc-danoﬂoxacin complex as a model for infection imaging S1929inconveniences and limitations of the conventional infection
imaging agents such as time-consuming preparation, the lack
of speciﬁcity, sensitivity and high radiation burden, the
development of new radiopharmaceuticals for infection imag-
ing represents a major challenge for nuclear medicine and
molecular imaging (Singh et al., 2003; Martin-Comin et al.,
2004; Sakr et al., 2013 and Moustapha et al., 2011).
Several radiolabeled antibiotics have been synthesized and
are potentially promising kits for the diagnostic imaging of
infective lesions (Singh et al., 2010; Esposito et al., 2009;
Asikoglu et al., 2000 and Brunton and Parker, 2008). The ideal
radiolabeled antibiotic agents should highly localize in the
infectious foci, where they are frequently taken up, metabo-
lized and display fast clearance from the body. Quinolones
(ceftriaxone, norﬂoxacin, sitaﬂoxacin, enroﬂoxacin, ciproﬂox-
acin, lomeﬂoxacin, sparﬂoxacin, diﬂoxacin, levoﬂoxacin,
peﬂoxacin, moxiﬂoxacin and ceftizoxime) are broad spectrum
antibiotics that are widely used as the major treatment of seri-
ous bacterial infections (Hazari et al., 2009; Nieto et al., 2005;
Starovoitova et al., 2014; Anderson and Kodukula, 2014 and
Ziessman et al., 2014). Ciproﬂoxacin labeled with 99mTc is con-
sidered as one of the most important radiopharmaceuticals
commercially available for infection imaging (Chattopadhyay
et al., 2010; Dumarey et al., 2002; Gemmel et al., 2004 and
IAEA, 2008). However, data of biodistribution in experimen-
tal animals and in human studies reported that the speciﬁcity
of 99mTc-ciproﬂoxacin for infection is contradictory (Yapar
et al., 2001; Sarda et al., 2002, 2003; Larikka et al., 2002a,b;
Siaens et al., 2004; Pauwels et al., 2001). 99mTc-ciproﬂoxacin
preparation has many disadvantages which are discussed in
detail in the literatures (Signore et al., 2008; Siaens et al.,
2004; Zolle, 2007 and Britton et al., 1997).
Danoﬂoxacin is a ﬂuoroquinolone derivative with broad
spectrum antibacterial activity toward both Gram positive
and Gram negative pathogenic bacteria. The structure of
danoﬂoxacin is shown in Fig. 1 (USP/NF, 2008). The purpose
of the present study was to establish a simple and efﬁcient
method for synthesis and labeling danoﬂoxacin with 99mTc
as a potential infection imaging agent to reveal the sites of bac-
terial infections in vivo. The formulation of the labeled drug
will have to be optimized based on preclinical assessments with
respect to in vitro and in vivo stability, radiochemical purity
and pharmacokinetic studies in animals.
2. Materials and methods
Danoﬂoxacin (C19H20FN3O3; M.wt. = 357.37 g/mol) was
purchased from Sigma–Aldrich, USA. Whatman No. 1 paper
chromatography (PC) was obtained from Whatman Interna-
tional Ltd., Maidstone, UK. Technetium-99 m (t1/2 = 6 h)
was eluted as 99mTcO4
 from 99Mo/99mTc generator, Gentech,N
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Figure 1 Chemical structure of danoﬂoxacin.Turkey. Measurement of radioactivity was performed in a
Well-type NaI(Tl) gamma(c)counter. All reagents and solvents
used were of analytical reagent grade and used without further
puriﬁcation. Deionized water was used in all experiments.
2.1. Labeling procedure
99mTc-danoﬂoxacin was synthesized by direct reaction of
danoﬂoxacin with technetium-99m. An accurate amount of
1 mg danoﬂoxacin was transferred to an evacuated penicillin
vial. A freshly prepared deoxygenated aqueous solution con-
taining exactly 50 lg of SnCl2Æ2H2O was added and the pH
of the preparation was adjusted to 11 using phosphate buffer.
One ml of 99mTc eluate containing 400 MBq was introduced to
the above reaction mixture, mixed and left to react at room
temperature (25 C) under sterile conditions for 30 min before
estimating the yield of the produced complex. The reaction
conditions affecting the radiolabeling yield such as stannous
chloride amount (25–200 lg), danoﬂoxacin amount (0.5–
2.5 mg), pH of the reaction mixture (5–12) and the reaction
time (1–480 min) were investigated and optimized in order to
maximize the labeling efﬁciency. Paper chromatography (PC)
and high performance liquid chromatography (HPLC) were
used to assess the radiochemical purity.
2.2. Analysis
Radiochemical purity of a radiopharmaceutical product is the
proportion of the total radioactivity in the desired radiochem-
ical form. Different analytical methods including PC and
HPLC are used to assess the radiochemical impurities present
in the reaction mixture with the 99mTc-labeled complex. Radio-
chemical impurities are hydrolyzed 99mTc and free 99mTcO4 .
Radiochemical purity of 99mTc-danoﬂoxacin was determined
by the ascending paper chromatographic technique using strips
of Whatman No. 1 paper chromatography (PC). Two strips
(1 cm width, 13 cm length) were marked 2 cm from the bottom
edge of the strip and lined into segments 1 cm each up to
13 cm. A spot of 1–2 ll of the ﬁltered reaction mixture contain-
ing the labeled complex was applied above the lower edge and
allowed to evaporate spontaneously. Then one strip was
placed in a closed jar and developed with acetone to determine
the percentage of free pertechnetate (99mTcO4
) while the other
strip was developed with a mixture of ethanol: water: ammonia
(2:5:1) to detect the percentage of reduced hydrolyzed techne-
tium-99m. After complete development the strips were
removed, dried and cut into segments of 1 cm each. The radio-
activity was counted using a Well-type c-scintillation detector.
The radiochemical purity was further conﬁrmed by HPLC.
Chromatographic analysis was performed by injection of 10 ll
of puriﬁed reaction mixture containing 99mTc-danoﬂoxacin at
the optimum conditions into a reversed-phase column (Lichro-
sorb RP C-18, 4 mm · 250 mm; 5 lm) coupled to a UV detec-
tor (SPD-6A) set at 320 nm and eluted with a mobile phase
consisting of a mixture of 10% ethanol in 0.2 M phosphate
buffer at pH 7.2. The ﬁltered mobile phase was degassed prior
to use and the ﬂow rate was adjusted to 0.5 ml/min.
(Moustapha et al., 2013; Al-wabli et al., 2011). Radioactivity
measurements in the HPLC eluates were detected by NaI(Tl)
scintillation detector coupled to a single channel analyzer.
S1930 M. Eid Moustapha et al.2.3. Stability of 99mTc-danoﬂoxacin in serum
Stability of the labeled complex was determined by mixing
1.8 ml of the normal serum and 0.2 ml of 99mTc-danoﬂoxacin
at 37 C for 24 h. During the in vitro incubation period, ali-
quots of 0.2 ml each were withdrawn at different time intervals
for up to 24 h and analyzed using instant thin layer chroma-
tography (ITLC) and HPLC to determine the percentage of
the formed 99mTc-complex, reduced hydrolyzed technetium
and free pertechnetate.
2.4. Induction of inﬂammation in mice
Induction of infectious foci was evaluated by the method
reported by Al-wabli in which a single clinical isolation of
Staphylococcus aureus from biological samples was used to
produce focal infection (Al-wabli et al., 2011). Individual col-
onies were diluted in order to obtain turbid suspension.
Groups of three mice were intramuscularly injected with
200 ll of the suspension in the left lateral thigh muscle. Then,
the mice were left for 24 h to get a gross swelling in the infected
thigh. On the other hand, non-infected inﬂammation (sterile
inﬂammation) was induced by injecting 200 ll of turpentine
oil sterilized by autoclaving at 121 C for 20 min., intramuscu-
larly administered in the left lateral thigh muscle of the mice.
Two days later, swelling appeared (Mostafa et al., 2010;
Asikoglu et al., 2000). Similarly, induction of heat killed
non-infected inﬂammation was induced by injecting 200 ll of
heat killed S. aureus (Larikka et al., 2002a,b; Oyen et al.,
2001 and Kaul et al., 2013).
2.5. Biodistribution studies
In vivo experiments were conducted in accordance with the
guidelines of the Egyptian Atomic Energy Authority and the
animal ethics committee. Prior to the biodistribution experi-
ment, normal Albino mice were housed in groups (n= 5) for
different intervals of time under normal conditions. Animals
were injected intravenously in the tail vein with 100 ll of
99mTc-danoﬂoxacin (4 MBq). Mice were sacriﬁced by cervical
dislocation at 2, 4 and 24 h after administration of 99mTc-
danoﬂoxacin. A blood sample was obtained by heart puncture.
Both target and non-target thighs were dissected and counted.
After dissection, the organs were removed, washed with saline,
collected in plastic tubes and weighed. The radioactivity of
each sample and the background was counted in a Well-type
NaI(Tl) gamma spectrometer. Results were reported as per-
cent-injected dose per gram organ (% ID/g organ ± SD) in
a population of ﬁve mice for each time point. Statistics are
evaluated with the Student’s t test and all results are given as
mean ± SEM.3. Results and discussion
Radiochemical purity and in vitro stability of 99mTc-danoﬂox-
acin complex were assessed by PC and further conﬁrmed by
HPLC. Acetone was used as the developing solvent to
determine free 99mTcO4
, which moved with the solvent front
(Rf = 1), while
99mTc-danoﬂoxacin and reduced hydrolyzed
technetium remained at the origin (Rf = 0). Reducedhydrolyzed technetium was detected using a mixture of etha-
nol: water: ammonium hydroxide (2:5:1 v/v) as the developing
solvent, where it remains at the origin (Rf = 0) while other spe-
cies migrate with the solvent front (Rf = 1). The undesirable
radiochemical species such as the free and hydrolyzed fractions
must be removed or reduced to a minimum level in order not
to change the biodistribution of the labeled compound result-
ing in a signiﬁcant interference with the diagnostic image. The
radiochemical purity was determined by subtracting the sum of
the percent of reduced hydrolyzed technetium and free per-
technetate from 100%. The radiochemical yield is the mean
value of three experiments. The radiochemical purity was fur-
ther conﬁrmed by HPLC analysis, where the retention time of
free 99mTcO4
 and 99mTc-danoﬂoxacin was 5 and 18.9 min,
respectively as illustrated in the radiochromatogram (Fig. 2).
In other words, quality control and puriﬁcation of
99mTc-danoﬂoxacin were performed by HPLC. It was able to
separate the labeled compound from the unlabeled compound
and the free pertechnetate. Factors affecting the labeling yield
will be discussed in detail.
3.1. Effect of danoﬂoxacin amount
Danoﬂoxacin was labeled with technetium-99m using the
direct technique in which the reduced technetium-99m reacted
with danoﬂoxacin to form the labeled chelate. The inﬂuence of
labeling yield on the amount of danoﬂoxacin actually present
in the reaction mixture is illustrated in Fig. 3. The reaction
was performed at different danoﬂoxacin amounts (0.5–
2.5 mg). Exactly 1 mg was the optimum ligand amount
required to obtain maximum radiochemical yield, 90 ± 2%.
Below this value, the ligand amount was insufﬁcient to com-
plex all the reduced technetium-99m toward the formation of
99mTc-danoﬂoxacin, as a result the reduced hydrolyzed techne-
tium was 53% at 0.5 mg of danoﬂoxacin. At ligand amount
above 1 mg, the yield slightly decreased but did not change
substantially and remained stable.
3.2. Effect of stannous chloride amount
Stannous chloride (SnCl2Æ2H2O) is the most commonly used
reducing agent for the reduction of the pertechnetate ion
(99mTcO4 ), having the oxidation state (VII) to lower oxidation
state, which favors its chelation by danoﬂoxacin. The labeling
process was affected by the amount of stannous chloride pres-
ent in the labeling reaction as demonstrated in Fig. 4. The
labeling yield of 99mTc-danoﬂoxacin was 73% after adding
25 lg SnCl2Æ2H2O to the reaction mixture. This may be attrib-
uted to incomplete reduction of 99mTcO4 and hence unreliable
yield of the complex due to the presence of free 99mTcO4
(13%). The labeling yield was maximized signiﬁcantly (90%)
by increasing the amount of SnCl2Æ2H2O from 25 to 50 lg.
Increasing the amount of SnCl2Æ2H2O to 200 lg leads to a sub-
stantial decrease in the labeling yield (48%) due to the forma-
tion of tin colloids (52%). Increasing the amount of
SnCl2Æ2H2O above the optimum value (50 lg) leads to compe-
tition of danoﬂoxacin for the reduced 99mTc. The formation of
the undesired tin colloid may be explained according to the
fact that most of the ligand molecules were consumed in the
formation of complex, hence the reduced pertechnetate may
form 99mTc–Sn-colloid and other Sn-complexes in the absence
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Figure 2 HPLC radiochromatogram of 99mTc danoﬂoxacin.
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Figure 3 Effect of substrate content on the percent labeling yield
of 99mTc-danoﬂoxacin complex.
0 50 100 150 200 250
0
10
20
30
40
50
60
70
80
90
100
 %99m Tc-danofloxacin complex
 % (RH-99m Tc) of danofloxacin
 % Free99m TcO4
-
 of danofloxacin
%
 
La
be
lin
g 
yi
el
d
SnCl2 amount , µg
Figure 4 Effect of SnCl2.2H2O content on the percent labeling
yield of 99mTc-danoﬂoxacin complex.
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Figure 5 Effect of pH value of the reaction mixture on the
percent labeling yield of 99mTc-danoﬂoxacin complex.
Tc-danoﬂoxacin complex as a model for infection imaging S1931of the ligand. On the other hand, the raise of stannous chloride
amount leads to the formation of stannous hydroxide colloid
Sn(OH)3
 impurities in alkaline medium, which in turn com-
pete with the chelation process of danoﬂoxacin and thusreduces the yield of the 99mTc chelate (Jurisson and Lydon,
1999; Saha, 2004).
3.3. Effect of pH
The labeling yield was affected by changes in pH of the reaction
mixture as illustrated in Fig. 5. At pH 11 the labeling efﬁciency
of 99mTc-danoﬂoxacin was equal to 90 ± 2%. The maximum
yield may be due to the deprotonation of the danoﬂoxacin at
high pH values, which increased the stability of 99mTcO(V)-
danoﬂoxacin complex. At alkaline pH values, the presence of
high OH- concentration in the reaction mixture may lead to
the partial hydrolysis of the formed complex and incomplete
reduction of 99mTc to the desired oxidation state, and hence
produce an unreliable yield of the 99mTc-danoﬂoxacin besides
the unreacted 99mTcO4 .
3.4. Effect of in vitro stability of 99mTc-danoﬂoxacin and
reaction time
Fig. 6 indicates that the rate of formation of 99mTc-danoﬂoxacin
complex was strongly dependent on reaction time. The labeling
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Figure 6 Effect of reaction time on 99mTc-danoﬂoxacin complex.
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Figure 7 Stability test for 99mTc-danoﬂoxacin.
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time from 1 to 30 min. In vitro stability of 99mTc-danoﬂoxacin
was investigated over time. Fig. 7 indicates that the labeled ﬂuo-0 5 10
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Figure 8 In vitro stability of 99mTcroquinolone derivative was stable for up to 120 min after label-
ing. The stability was found to be time-dependent with respect
to some factors such as temperature, light and radiolysis, which
may lead to the decomposition of the compound and limited its
availability prior to injection.
3.5. Stability test
As shown in Fig. 8, incubation of 99mTc-danoﬂoxacin in
normal serum for 24 h at 37 C resulted in a small release
of radioactivity (13 ± 1%, n= 5 experiments) from the
99mTc-complex, as determined by HPLC and ITLC. Therefore,
the stability of the labeled complex indicated its suitability for
in vivo application over time.
3.6. Biodistribution
Biodistribution data of the mice infected with living, heat
killed S. aureus and turpentine oil are shown in Table 1. The
uptake of 99mTc-danoﬂoxacin was signiﬁcantly low in heat
killed S. aureus and turpentine oil infected animals (aseptic
inﬂammation) as compared to infected animals with living bac-
teria (abscess). These data indicated high uptake in the
inﬂamed areas within 2 h after intravenous administration of
the labeled compound via the tail vein. A rapid distribution
of radioactivity was observed throughout the body. The
uptake of 99mTc-danoﬂoxacin in different organs demon-
strated that the injected tracer was cleared from the blood
stream 24 h post injection. The major remaining activity of
the tracer was found in the kidneys (6.6 ± 0.4% ID) and urine
(30 ± 3% ID). In contrast, a signiﬁcant level of radioactivity
was retained in the liver (5.4 ± 0.3% ID). Elimination of
99mTc-danoﬂoxacin appeared to be by both renal and hepatic
routes.
Mice with infectious lesions injected with 99mTc-ﬂuoroquin-
olone revealed a mean abscess-to-muscle (target to non-target,
T/NT) ratio equal to 7.2 ± 0.1 after 2 h post injection, which
express higher uptake in infected tissue than the commercially
available 99mTc-ciproﬂoxacin (T/NT = 3.8 ± 0.8) (Rien et al.,
2004) as shown in Fig 9.15 20 25
 %
99m
Tc-danofloxacin
n time, hour
-danoﬂoxacin in normal serum.
Table 1 Biodistribution of 99mTc-danoﬂoxacin in Staphylococcus aureus, heat killed Staphylococcus aureus and turpentine oil inﬂamed
mice at different time intervals.
Organs and body ﬂuids % Injected dose/organs at diﬀerent time intervals (h)
S. aureus Heat killed S. aureus Turpentine oil
2 4 24 2 4 24 2 4 24
Inﬂamed muscle 1.8 ± 0.2 1.3 ± 0.1 0.8 ± 0.1 0.97 ± 0.1 0.75 ± 0.2 0.25 ± 0.1 1.1 ± 0.0 0.69 ± 0.2 0.21 ± 0.1
Control muscle 0.25 ± 0.1 0.21 ± 0.2 0.19 ± 0.0 0.29 ± 0.0 0.26 ± 0.1 0.15 ± 0.0 0.30± 0.0 0.25 ± 0.0 0.13 ± 0.0
Liver 17.1 ± 3.2 12.9 ± 2.0 5.4 ± 0.3 17.6 ± 2.4 12.2 ± 2.2 4.9± 0.5 17.5 ± 3.0 13.2 ± 2.2 6.1 ± 0.6
Urine 18.5 ± 3.5 24.9 ± 4.2 29.9 ± 3.1 17.1 ± 1.3 24.3 ± 1.1 29.4 ± 2.7 18.0 ± 0.9 25.4 ± 1.8 28.8 ± 2.4
Kidneys 11.2 ± 1.2 10.7 ± 1.3 6.6 ± 0.4 10.9 ± 1.3 10.2 ± 2.3 5.5 ± 0.7 11.3 ± 2.5 10.2 ± 1.2 6.9 ± 0.3
Blood 5.3 ± 0.4 3.1 ± 0.2 1.00 ± 0.0 6.10 ± 0.2 4.0 ± 0.2 1.0 ± 0.1 5.5 ± 0.2 4.3 ± 0.2 1.0 ± 0.0
Heart 0.3 ± 0.1 0.1 ± 0.0 0.09 ± 0.0 0.3 ± 0.09 0.1 ± 0.0 0.1 ± 0.0 0.4 ± 0.08 0.2 ± 0.0 0.1 ± 0.0
Lung 1.2 ± 0.2 0.2 ± 0.0 0.1 ± 0.0 1.1 ± 0.09 0.2 ± 0.0 0.1 ± 0.0 1.3 ± 0.09 0.4 ± 0.1 0.2 ± 0.0
Intestine and stomach 19.9 ± 2.5 3.90 ± 0.5 2.10 ± 0.3 19.1 ± 3.4 4.7 ± 0.4 2.2 ± 0.7 18.9 ± 1.9 4.7 ± 0.8 2.4 ± 0.4
Spleen 2.10 ± 0.1 1.00 ± 0.2 0.3 ± 0.1 2.1 ± 0.3 1.1 ± 0.0 0.5 ± 0.1 2.0 ± 0.1 1.3 ± 0.0 0.3 ± 0.0
Bone 0.90 ± 0.0 0.40 ± 0.1 0.10 ± 0.0 1.0 ± 0.0 0.49 ± 0.1 0.1 ± 0.0 1.1 ± 0.2 0.5 ± 0.1 0.1 ± 0.0
2 4 22 24 26
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Figure 9 The ratio of target muscle (T) to non-target muscle
(NT) of 99mTc-danoﬂoxacin in different inﬂammation models at
different post injection times.
Tc-danoﬂoxacin complex as a model for infection imaging S19334. Conclusions
This study characterized the in vitro and in vivo conditions nec-
essary for designing 99mTc-danoﬂoxacin complex as a poten-
tially useful radiopharmaceutical for diagnosing bacterial
infection. Danoﬂoxacin was successfully labeled with techne-
tium-99m by the direct labeling method at room temperature
with a labeling yield of 90% using stannous chloride as a
reducing agent. The excellent localization of the tracer in the
induced foci of inﬂammation expressed the effectiveness of this
complex for targeting infectious lesions, which was higher than
the commercially available 99mTc-ciproﬂoxacin.
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